ESC 365 - Cangrelor versus no cangrelor during percutaneous coronary intervention in hemodynamically unstable patients: a cohort study on benefits and risks

ESC Professional Premium Access

Cangrelor versus no cangrelor during percutaneous coronary intervention in hemodynamically unstable patients: a cohort study on benefits and risks

Session: Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention

Topic: Antiplatelet Drugs

Speaker: Mr O. Emilsson (Lund, SE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Oskar Love Emilsson

Lund University, Lund (Sweden)

0 follower

5 more presentations in this session

P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis

Speaker: Doctor M. Galli (Rome, IT)

Clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention - a nationwide population-based study

Speaker: Mr J. Cho (Seoul, KR)

Implementation of prasugrel and prognostic outcomes after percutaneous coronary intervention for myocardial infarction: a nationwide observational study

Speaker: Doctor M. Jacobsen (Copenhagen, DK)

Impact of different P2Y12 inhibitors in acute coronary syndrome patients with severe chronic kidney disease: insights from the CORALYS registry

Speaker: Doctor F. Giacobbe (Turin, IT)

Pretreatment with dual antiplatelet therapy in acute myocardial infarction

Speaker: Professor Z. Motovska (Prague, CZ)

Access the full session

Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention

Speakers: Mr O. Emilsson, Doctor M. Galli, Mr J. Cho, Doctor M. Jacobsen, Doctor F. Giacobbe...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources